

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (withdrawn-previously presented) A method of extending survival and/or delaying disease progression by treating a human tumor in a mammal, wherein said tumor expresses an antigen which specifically binds to a monoclonal antibody or antigen binding fragment thereof which has the identifying characteristics of a monoclonal antibody encoded by a hybridoma deposited with the ATCC as accession number PTA-5691 comprising administering to said mammal said monoclonal antibody in an amount effective to reduce said mammal's tumor burden, whereby disease progression is delayed and/or survival is extended.

Claim 2. (withdrawn) The method of claim 1 wherein said antibody is conjugated to a cytotoxic moiety.

Claim 3. (withdrawn) The method of claim 2 wherein said cytotoxic moiety is a radioactive isotope.

Claim 4. (withdrawn) The method of claim 1 wherein said antibody activates complement.

Claim 5. (withdrawn) The method of claim 1 wherein said antibody mediates antibody dependent cellular cytotoxicity.

Claim 6. (withdrawn) The method of claim 1 wherein said antibody is a murine antibody.

Claim 7. (withdrawn) The method of claim 1 wherein said antibody is a humanized antibody.

Claim 8. (withdrawn-previously presented) The method of claim 1 wherein said antibody is a chimeric antibody.

Claim 9. (withdrawn-previously presented) The isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as PTA-5691.

Claim 10. (withdrawn-previously presented) A humanized antibody of the isolated monoclonal antibody of claim 9.

Claim 11. (withdrawn-previously presented) A chimeric antibody of the isolated monoclonal antibody of claim 9.

Claim 12. (withdrawn) Antigen binding fragments of the isolated monoclonal antibody of claim 9.

Claim 13. (withdrawn) Antigen binding fragments of the humanized antibody of claim 10.

Claim 14. (withdrawn-previously presented) Antigen binding fragments of the chimeric antibody of claim 11.

Claim 15. (withdrawn) The isolated antibody or antigen binding fragments of any one of claims 9, 10, 11, 12, 13 or 14 conjugated with a member selected from the group consisting of cytotoxic moieties, enzymes, radioactive compounds, and hematogenous cells;

whereby antibody conjugates are formed.

Claim 16. (withdrawn-previously presented) The isolated hybridoma deposited with the ATCC as PTA-5691.

Claim 17. (withdrawn-previously presented) A binding assay to determine presence of cancerous cells in a tissue sample selected from a human tumor comprising:

providing a tissue sample from said human tumor;

providing an isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as PTA-5691, or an antigen binding fragment thereof, or an antibody conjugate thereof;

contacting said isolated monoclonal antibody or antigen binding fragment thereof or antibody conjugate thereof with said tissue sample; and

determining binding of said isolated monoclonal antibody or

antigen binding fragment thereof or antibody conjugate thereof with said tissue sample;

whereby the presence of said cancerous cells in said tissue sample is indicated.

Claim 18. (withdrawn) The binding assay of claim 17 wherein the human tumor tissue sample is obtained from a tumor originating in a tissue selected from the group consisting of ovarian and breast tissue.

Claim 19. (withdrawn-previously presented) A process of isolating or screening for cancerous cells in a tissue sample selected from a human tumor comprising:

providing a tissue sample from said human tumor;

providing an isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as PTA-5691, or an antigen binding fragment thereof, or an antibody conjugate thereof;

contacting said isolated monoclonal antibody or antigen binding fragment thereof or antibody conjugate thereof with said tissue sample; and

determining binding of said isolated monoclonal antibody or antigen binding fragment thereof or antibody conjugate thereof with said tissue sample;

whereby said cancerous cells are isolated by said binding and their presence in said tissue sample is confirmed.

Claim 20. (withdrawn) The process of claim 19 wherein the human tumor tissue sample is obtained from a tumor originating in a tissue selected from the group consisting of ovarian and breast tissue.

Claim 21. (previously presented) The isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as Accession Number PTA-5690.

Claim 22. (Currently amended) A humanized antibody [[of]]
produced from the isolated monoclonal antibody of claim 21.

Claim 23. (Cancelled)

Claim 24. (original) Antigen binding fragments of the isolated monoclonal antibody of claim 21.

Claim 25. (original) Antigen binding fragments of the humanized antibody of claim 22.

Claim 26. (Cancelled)

Claim 27. (Currently amended) The isolated monoclonal antibody or antigen binding fragments of any one of claims 21, 22,

[[23,]] 24, 25 or [[26]] conjugated with a member selected from the group consisting of ~~cytotoxic moieties~~ toxins, enzymes, radioactive compounds, and hematogenous cells;
~~whereby antibody conjugates are formed.~~

Claim 28. (previously presented) The isolated hybridoma deposited with the ATCC as Accession Number PTA-5690.

Claim 29. (withdrawn-previously presented) A binding assay to determine presence of cancerous cells in a tissue sample selected from a human tumor comprising:

providing a tissue sample from said human tumor;

providing an isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as Accession Number PTA-5690 or antigen binding fragment thereof; or an antibody conjugate thereof;

contacting said isolated monoclonal antibody or antigen binding fragment thereof or antibody conjugate thereof with said tissue sample; and

determining binding of said isolated monoclonal antibody or antigen binding fragment thereof or antibody conjugate thereof with said tissue sample;

whereby the presence of said cancerous cells in said tissue sample is indicated.

Claim 30. (withdrawn) The binding assay of claim 29 wherein the human tumor tissue sample is obtained from a tumor originating in a tissue selected from the group consisting of colon tissue.

Claim 31. (withdrawn-previously presented) A process of isolating or screening for cancerous cells in a tissue sample selected from a human tumor comprising:

providing a tissue sample from a said human tumor;

providing an isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as Accession Number PTA-5690 or antigen binding fragment thereof; or an antibody conjugate thereof;

contacting said isolated monoclonal antibody or antigen binding fragment thereof or antibody conjugate thereof with said tissue sample; and

determining binding of said isolated monoclonal antibody or antigen binding fragment thereof or antibody conjugate thereof with said tissue sample;

whereby said cancerous cells are isolated by said binding and their presence in said tissue sample is confirmed.

Claim 32. (withdrawn) The process of claim 31 wherein the human tumor tissue sample is obtained from a tumor originating in a tissue selected from the group consisting of colon tissue.